Novel therapeutic and diagnostic products and methods
OwnerPer Svenningsson, Paul Greengardinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of p11 as a drug target as well as a tool for the diagnosis, treatment and development of p11/5-HT receptor related disorders. The invention further relates to p11 knock-out animals as well as p11 transgenic animals and their use as models for the development of novel psychotherapeutic agents, and to methods of diagnosis, prophylaxis and treatment of p11/5-HT receptor related disorders.
Claims39
A method of diagnosing a p11/5-HT receptor related disorders in a subject comprising determining the level of p11 in a biological sample from said subject and comparing said p11 level to a reference, wherein an abnormal level of p11 compared to the reference constitutes a positive diagnosis of p11/5-HT receptor related disorder.
A method to identify modulators useful to treat or ameliorate p11/5-HT receptor related disorders comprising the steps of:
- a) providing a first sample and a second sample containing equivalent amounts of p11 gene product;
- b) contacting the first sample with the candidate p11 modulator;
- and
- c) determining whether the amounts of p11 gene product in the first sample has increased or decreased relative to the amounts of p11 gene product in the second sample not contacted with the candidate p11 modulator, wherein an increased amount of gene product indicate that the candidate modulators can be useful to treat or ameliorate disorders associated with abnormally low level of p11 while a decreased amount of gene products indicates that the candidate modulators can be useful to treat or ameliorate disorders associated with abnormally high level of p11.
A method to identify modulators useful to treat or ameliorate p11/5-HT receptor related disorders comprising the steps of:
- a) providing a first sample and a second sample containing equivalent number of 5-HT1B receptors at cell surface;
- b) contacting the first sample with the candidate p11 modulator;
- and
- c) determining whether the number of 5-HT1B receptors at cell surface of the first sample has increased relative to the second sample, wherein an increased number of 5-HT1B receptors at cell surface indicate that the candidate modulators can be useful to treat or ameliorate disorders associated with abnormally low level of p11 activity while a decreased amount of 5-HT1B receptors at cell surface indicates that the candidate modulators can be useful to treat or ameliorate disorders associated with abnormally high level of p11 activity.
A method to identify p11 mimetics useful to treat or ameliorate p11/5-HT receptor related disorders comprising assaying for the ability of a candidate p11 mimetic to recruit 5-HT1B receptors to the neuronal plasma membrane.
A method of treating or ameliorating p11 dysfunction in a subject diagnosed as suffering from one or more p11/5-HT receptor related disorders comprising administering to said subject a therapeutically effective amount of a p11 modulator or p11 mimetic.
A p11 knock-out non-human mammal wherein said mammal has a defect, mutation or deficiency in the p11 gene compared to wild-type mammals of the same species.
A method of studying p11/5-HT receptor related disorders or to develop novel psychotherapeutic agents useful for the treatment of p11/5-HT receptor related disorders comprising:
- a) administering an effective amount of said psychotropic agent to p11 knock-out mice and control mice;
- b) assessing the levels of p11 level and/or behavioral responses to said agent in said p11 knock-out mice and control mice;
- c) comparing said p11 level and/or behavioral responses in p11 knock-out mice with control mice.
A non-human mammal comprising a transgene encoding p11 under control of a regulatable promoter.
A method to enhance p11 expression in a patient suffering from a p11/5-HT receptor related disorder, comprising the administration of a nucleic acid which enhances the expression of p11 in the brain of said patient.
Dependencies are inferred from the claim text.